Welcome to our dedicated page for HeartSciences news (Ticker: HSCS), a resource for investors and traders seeking the latest updates and insights on HeartSciences stock.
HeartSciences Inc. reports developments as a healthcare information technology company advancing electrocardiography through artificial intelligence. The company’s MyoVista Insights platform is a cloud-native, device-agnostic ECG management system designed for workflow efficiency, EHR interoperability and deployment of cleared AI-ECG algorithms in clinical workflows.
Recurring updates include commercialization of MyoVista Insights, customer and reference-site agreements with hospitals, health networks and academic programs, interoperability milestones such as Epic Toolbox designation, financial results and shareholder meeting matters. HeartSciences also discusses its MyoVista wavECG device, which is designed to provide conventional ECG functionality while supporting on-device AI-enabled solutions.
Fortitude Mining Holdings completed the cash-funded acquisition of a 12.5 MW digital infrastructure facility in Prosser, Nebraska, purchasing the underlying real property and improvements for a $6.25 million purchase price. Consideration included an approximately $985,000 hosting deposit credit and about $465,500 of T21 miners credited against the price, resulting in net new cash to close of roughly $4.7 million, reflecting prior power deposits.
The Prosser Facility becomes Fortitude’s third Nebraska site and contributes to an owned power portfolio of over 60 MW of contracted power across seven U.S. sites. According to Fortitude, the site offers an estimated stabilized power cost of about $0.045/kWh, full infrastructure ownership including a 67 kV substation, and participation in Southwest Power Pool market pricing and demand response programs. The company links this acquisition to its venture mining strategy and to building scale ahead of its proposed business combination with HeartSciences (Nasdaq: HSCS).
Fortitude Mining Holdings executed a definitive purchase agreement with Bitmain for 9,000 Antminer Z15 Pro Equihash ASIC miners, supporting its proposed business combination with HeartSciences (Nasdaq: HSCS). Units are scheduled to ship in two tranches: 3,000 in October 2026 and 6,000 in November 2026.
The per‑unit price is $3,499, for an aggregate equipment commitment of about $31.5 million/b. Fortitude believes this is roughly prevailing market pricing for comparable Q4 2026 batches. Based on Bitmain’s published specifications, the order represents about 7.56 GSol/s of incremental Equihash hashrate, to be deployed across Fortitude’s over 60 MW of contracted power capacity at seven U.S. sites.
For the six months ended June 30, 2026, Fortitude mined 72,696 ZEC, which the company estimates was approximately 28.0% of total network ZEC production, implying an annualized rate of about 146,730 ZEC (roughly 402 ZEC per day).
HeartSciences (Nasdaq: HSCS) filed a preliminary proxy statement for its proposed business combination with Fortitude Mining Holdings and reported fiscal 2026 results for the year ended April 30, 2026. The unaudited pro forma statement in the proxy assumes issuance of approximately 107.6 million shares of new Class V common stock to Digital Currency Group, Fortitude’s parent, and shows pro forma combined shareholders’ equity of $70.0 million.
Fortitude, a U.S.-based Zcash-focused mining platform, mined 72,696 ZEC in the six months ended June 30, 2026, about 28% of overall ZEC production, and is expanding capacity toward an owned power portfolio of over 60MW. HeartSciences fully launched its MyoVista Insights AI-ECG software platform with initial deployments and submitted its MyoVista wavECG device to the FDA for 510(k) clearance, which remains under review. HeartSciences reported no meaningful revenue in fiscal 2026, ended the year with $1.7 million in cash and cash equivalents and $0.2 million in shareholders’ equity, and is also asking shareholders to approve a potential 1-for-2 to 1-for-5 reverse stock split to support Nasdaq listing requirements for the combined company.
Fortitude Mining Holdings announced it has energized a new 12 MW Grand Island, Nebraska facility, its first greenfield build, completing construction, bringing the site online, and validating electrical infrastructure ahead of full-scale operations. The project expands Fortitude’s contracted owned power portfolio to over 60 MW across seven sites in South Dakota, Nebraska, Texas, and New York.
According to Fortitude, the Grand Island Facility is expected to operate at an estimated power cost of about $0.045/kWh and, assuming successful equipment deployment and stable conditions, contribute to lowering Zcash direct cash mining costs from roughly $70 per coin toward about $40 per coin. The site is positioned between two solar facilities and next to a substation with historically excess capacity, designed as a flexible, interruptible load that can curtail during peak demand, and is not expected to use water or increase ambient sound at adjacent property lines. The milestone follows the previously announced definitive agreement for a proposed business combination with HeartSciences (Nasdaq: HSCS).
HeartSciences (Nasdaq: HSCS) has filed its Annual Report on Form 10-K for fiscal year ended April 30, 2026 with the SEC, available on sec.gov and the company’s website.
HeartSciences expects to file shortly a preliminary proxy statement for its proposed business combination with Fortitude Mining Holdings, an institutional-scale, vertically integrated Proof-of-Work venture mining platform currently wholly-owned by Digital Currency Group. The company believes the Proposed Transaction offers shareholders continued ownership in a revenue-generating, at-scale business backed by an established investor, while allowing its MyoVista Insights AI-ECG technology to advance with greater focus. Following the proxy filing, HeartSciences plans to issue its fiscal 2026 earnings release and a business update, currently expected early next week. CEO Andrew Simpson described fiscal 2026 as a landmark year marked by the launch of MyoVista Insights and the beginning of a transition to mainstream commercial revenue.
Fortitude and HeartSciences (Nasdaq: HSCS) signed a definitive all-stock merger agreement, targeting close in H2 2026. The combined company will operate as Fortitude, led by Fortitude CEO Andrea Childs, and is expected to trade on Nasdaq as “TUDE”, subject to approval.
Fortitude is a vertically-integrated Zcash-focused venture mining platform, currently owned by Digital Currency Group, with annualized production of 157,000 ZEC. DCG is expected to own about 95% of the combined company at closing.
HeartSciences (Nasdaq: HSCS) received European Patent No. EP4252651 for ECG-based assessment of diastolic function, effective as a Unitary Patent from April 29, 2026.
The patent covers AI-driven machine-learning models using ECG and demographic data, extends protection to 19 European countries, and brings HeartSciences’ portfolio to more than 45 granted patents.
HeartSciences (Nasdaq: HSCS) released MyoVista Insights 1.3, introducing an AI-ECG Algorithm Marketplace and integrating Bunkerhill Health’s FDA-cleared ECG-EF algorithm for detecting reduced ejection fraction (LVEF ≤40%) from routine 12-lead ECGs.
AI-ECG assessments are eligible for 2026 Medicare reimbursement under APC 5734 at about $136 per assessment, supporting a recurring SaaS revenue model.
HeartSciences (Nasdaq: HSCS) signed a commercial agreement with North Shore Health to deploy its MyoVista Insights ECG management platform. North Shore is the first hospital deployment within the Cibolo Health network, which includes 127 independent hospitals. The deal represents SaaS-based revenue and advances HeartSciences’ AI-enabled ECG commercialization strategy.
HeartSciences (Nasdaq: HSCS) signed a commercial SaaS agreement with St. Vincent Health on May 5, 2026, marking its first mainstream revenue-generating deployment of MyoVista Insights™ after the platform's full launch at the American College of Cardiology annual session.
The cloud-native, device-agnostic ECG management platform is offered as recurring SaaS, supports EHR interoperability, cleared AI-ECG algorithms, and the company says it is in active commercial discussions with additional providers.